Kidney Cancer

Following the recent FDA approval of tivozanib in renal cell carcinoma (RCC), the VEGF-TKI is now being explored in combination with the PD-1 inhibitor nivolumab in the phase 3 TiNivo-2 trial in patients with relapsed/refractory RCC.

The FDA has approved tivozanib for kidney cancer.

The combination regimen shrank tumors and led to disease control in the majority of patients.

An expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.

The European Commission is reviewing data from the pivotal phase 3 CheckMate-9ER trial.

Adding the off-the-shelf, cell-based immunotherapy ilixadencel to frontline sunitinib was associated with an overall survival benefit in patients with metastatic renal cell carcinoma.

Motzer highlights the overall survival benefit achieved with the combination of the PD-1 inhibitor and the multikinase inhibitor versus standard sunitinib in the phase 3 CLEAR trial.

The study assessed factors associated with survival outcomes in patients with metastatic clear cell renal cell carcinoma receiving immune checkpoint inhibitors.

Published data show the PD-1 inhibitor induced strong antitumor activity in patients with both advanced clear cell renal cell carcinoma (ccRCC) and advanced non-ccRCC.

The phase 3 ZIRCON trial is assessing TLX250-CDx as a noninvasive tool to identify clear cell renal cell carcinoma in patients with indeterminate renal masses.

The approval is based on data from the phase 3 CheckMate-9ER trial.

Hear from key opinion leaders in the urology space as they discuss 2 complex cases across the multidisciplinary approach in upper tract urothelial carcinoma and an incidentally discovered renal mass.

Ramaprasad Srinivasan, MD, PhD, provides background on the prognosis and treatment of patients with Von Hippel-Lindau–associated renal cell carcinoma and highlights the novel agent MK-6482.

Register for a live, interactive event featuring leaders in oncology reviewing and discussing patient cases in Bladder Cancer/Renal Carcinoma.

A large review showed that cancer specific survival was improved in overweight and obese patients with renal cell carcinoma compared with patients with normal BMI.

Combining telaglenastat with cabozantinib did not improve outcomes versus cabozantinib alone in a phase 2 trial.

Improvements in technology have renewed interest in the technique.

Over 90% of patients in a phase 2 trial had at least some decrease in the size of target lesions.

The comprehensive review includes key developments in both clear cell and non-clear cell histology.

Recent research has revived the controversy regarding the role of cytoreductive nephrectomy in this setting.

Rana R. McKay, MD, highlights developments with immunotherapy and targeted agents in the treatment paradigm for non-clear cell renal cell carcinoma.

Findings from the phase 3 KEYNOTE-581/CLEAR trial (Study 307) showed that the combination improved overall survival, progression-free survival, and response versus sunitinib.

"There is unmet medical need in trying to determine if there is a differential benefit to using one therapy over another in the non-clear cell setting," Thomas E. Hutson, DO, PharmD.

Among a small group of patients with metastatic renal cell carcinoma who developed acute interstitial nephritis while on immune checkpoint therapy, 100% had a durable response to treatment.

At a median follow-up of over 2.5 years, the combination continued to show a significant benefit in overall and progression-free survival versus single-agent sunitinib.

Upfront nivolumab followed by response-dependent sequential use of ipilimumab did not optimize treatment outcomes in patients with advanced renal cell carcinoma.

The FDA is reviewing data from the phase 3 CheckMate-9ER trial, which showed that the combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.

"Currently, there is significant variability in the design, conduct, and analysis of clinical trials for adjuvant treatment of both kidney cancer and bladder cancer. This variability negatively affects our ability to interpret trial results," said Richard Pazdur, MD.

The results may help guide treatment selection with immunotherapy versus targeted agents in patients with kidney cancer.

The combination significantly improved progression-free and overall survival compared with sunitinib in frontline renal cell carcinoma.